Medicenna Therapeutics Corp. (NASDAQ: MDNA) stock declined by 1.74% at last close whereas the MDNA stock price gains by 6.64% in the pre-market trading. Medicenna is a medical immunotherapy business focusing on developing new, extremely selective variants of IL-2, IL-4, and IL-13 Superkines as well as first-in-class Empowered Superkines for the treatment of malignancies.
Upcoming Event for MDNA stock
On August 13, 2021, Medicenna Therapeutics Corp. will have a conference call and live webcast to discuss its first-quarter fiscal 2022 financial results and operating highlights.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
- Are You Looking for Dividend Paying Stocks? Here are the Best Buys in 2021
- Two Promising Pet Stocks for Investment as we Head 2021
MDNA Stock Recent Development
The MDNA11 program at Medicenna Therapeutics has been updated. Dr. Fahar Merchant, President, and CEO of Medicenna, gave the update alongside Dr. Mann Muhsin, Chief Medical Officer, and Ms. Elizabeth Williams, Chief Financial Officer, at the PropThink Digital conference on July 27, 2021.
The Phase 1/2 ABILITY Study of MDNA11 is being conducted by Medicenna to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of different dosages of MDNA11 given intravenously in patients with advanced solid tumors. As previously reported, the Phase 1/2 ABILITY Study will extend enrolment to clinical locations in the United States, the United Kingdom, and Canada, in addition to Australia.
Medicenna has filed a clinical trial request to an HREC in Australia to begin the Phase 1/2 ABILITY Study and intends to finish legal filings and clearances for other trial jurisdictions this year.
The Company expects to begin the Phase 1/2 ABILITY Study in Australia in the third quarter of 2021, as initially reported pursuing talks with Australian clinicians, investigators, contract research organizations, and clinical trial sites. All of these are involved in the survey about the condition of oncology clinical trials in Australia due to COVID-19-related government restrictions.
The following are some key insights from these talks:
- The treatment of medical problems is excluded from COVID-19-related travel limitations, according to these talks.
- Prior government-mandated lockdowns had little effect on Phase 1 cancer trial enrolment.
- Despite COVID-19-related limitations in several Australian jurisdictions, enrollment in Phase 1 oncology studies at locations involved in Medicenna’s MDNA11-01 Study has proceeded with no hurdles.